etanercept
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammation
Conditions
Inflammation, Psoriasis
Trial Timeline
Oct 1, 2004 → —
NCT ID
NCT00121615About etanercept
etanercept is a phase 3 stage product being developed by Amgen for Inflammation. The current trial status is completed. This product is registered under clinical trial identifier NCT00121615. Target conditions include Inflammation, Psoriasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00111111 | Phase 3 | Completed |
| NCT05135312 | Approved | UNKNOWN |
| NCT02749370 | Approved | Completed |
| NCT02274792 | Approved | Completed |
| NCT01971346 | Approved | Completed |
| NCT01543204 | Approved | Terminated |
| NCT01132235 | Approved | UNKNOWN |
| NCT01009879 | Approved | Withdrawn |
| NCT00833729 | Approved | Completed |
| NCT00640393 | Approved | Completed |
| NCT01053819 | Approved | Completed |
| NCT00477191 | Pre-clinical | Terminated |
| NCT00585650 | Phase 1/2 | Completed |
| NCT00413452 | Phase 3 | Completed |
| NCT00361634 | Phase 1 | Completed |
| NCT00333034 | Phase 3 | Completed |
| NCT00322439 | Pre-clinical | Completed |
| NCT00332332 | Approved | Completed |
| NCT00346294 | Approved | Completed |
| NCT00965666 | Phase 1 | Completed |
Competing Products
20 competing products in Inflammation